BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM

**01 March, 2024 (Friday) 14:00 – 16:40 Hrs**

**Bali, Indonesia Time**

**Singaraja 1**

### 14:00 – 14:30 Screening and Surgical Oncology

**Speaker:** PETER DUBSKY, SWITZERLAND

- **GS03-02:** Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
- **GS02-02:** Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study
- **GS02-06:** Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial
- **GS02-04:** Surgical Treatment of Women with Breast Cancer and a BRCA1 Mutation: An International Analysis of the Impact of Bilateral Mastectomy on Survival

### 14:30 – 15:00 Radiation Oncology

**Speaker:** FAYE LIM, SINGAPORE

- **GS02-07:** Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304
- **GS02-08:** Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomics-selected favourable Stage I breast cancer
- **GS03-01:** Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of E4112

### 15:00 – 15:30 Early-Stage Hormone Receptor Positive Breast Cancer

**Speaker:** JAVIER CORTES, SPAIN

- **GS1-01:** Biomarker results in high-risk estrogen receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer following neoadjuvant chemotherapy ±nivolumab: an exploratory analysis of CheckMate7FL
- **GS01-02:** Phase 3 study of neoadjuvant pembrolizumab or placebo plus
chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756

- GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial

- GS03-06: Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2−, node-positive, high-risk early breast cancer in the monarchE trial

15:30 - 16:00

Early stage Triple Negative Breast Cancer/HER2 positive Breast Cancer/Survivorship

Speaker: TIRA TAN, SINGAPORE

- GS01-03: Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial

- GS03-12: Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis

- GS02-11: Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy

- GS02-13: Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study

16:00 - 16:20

Advanced Triple Negative and HER2 positive negative Breast Cancer

Speaker: HOPE RUGO, USA

- GS01-05: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study

- GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
16:20 – 16:40 | Advanced ER Positive HER2 Negative Breast Cancer

Speaker: LEE SOO CHIN, SINGAPORE

- **GS02-01**: Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01

- **GS03-13**: Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis

- **GS01-12**: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer